Change in percentage between baseline and after 6 weeks of treatment with crizotinib assessed using SUV_max (1A, N = 13), SUV_peak (1B, N = 10) and RECIST (1C, N = 13).

Change in percentage between baseline and after 6 weeks of treatment with crizotinib assessed using SUVmax (1A, N = 13), SUVpeak (1B, N = 10) and RECIST (1C, N = 13).</p

¹⁸F-FDG maximum intensity projection of patient 2 and 8 prior to (A, B) and after 6 weeks of treatment with crizotinib (C, D).

<p>Scale is from 0–15 SUV. These images illustrate the clinically dramatic decrease in ¹⁸F-FDG uptake, with both patients having a PMR according to both PERCIST criteria and the EORTC recommendations.</p

Baseline patient characteristics.

<p>Baseline patient characteristics.</p

Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.

<p>Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.</p

Schematic representation of fusion gene products clustered at the <i>ALK</i> locus and selected fusions validation.

(A) Three fusion products clustered at a 25Mb genomic region including the ALK gene locus in the tumor of patient #3. Two of the three fusion products are the result of an inversion (EML4-ALK and MCFD2-CLIP4), whereas the third fusion product is generated via an eversion (CLIP4-VSNL1). EML4-ALK and CLIP4-VSNL1 contain a predicted ORF. (B) Detection of EML4-ALK fusion in three crizotinib post-treatment tumor samples (post 1, post 2 and post 3, corresponding to post-treatment samples of patient #1, #2 and #3 respectively). (C) Validation of three novel fusion genes in frozen post-treatment tumor sample of patient #3. (D) Detection of the fusion genes in FFPE samples of post-treatment samples and analysis of the fusion gene in pre-treatment tumor sample of patient #3. Norm: Normal lung tissue; Pre: pre-treatment tumor sample; Post: post-treatment tumor sample; Neg: Negative control.</p

List of primers for detection of fusion transcripts and <i>ALK</i> mutations in frozen and FFPE samples.

(DOCX)</p

NSCLC patient characteristics and<i>KRAS/EGFR</i> mutation^*.

<p>NSCLC patient characteristics and<i>KRAS/EGFR</i> mutation^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0152317#t003fn001" target="_blank">*</a>}.</p

NSCLC patient characteristics according to COPD status.

NSCLC patient characteristics according to COPD status.</p

Distribution of different <i>EGFR</i> mutations in advanced NSCLC patients.

<p>Distribution of different <i>EGFR</i> mutations in advanced NSCLC patients.</p

Logistic regression analysis of patient characteristics associated with COPD, <i>KRAS</i> and <i>EGFR</i>.

<p>Logistic regression analysis of patient characteristics associated with COPD, <i>KRAS</i> and <i>EGFR</i>.</p